OpenLB
Open Library of Bioscience
Advanced Search
Frontiers in immunology
2024;15 1438030.

Revolutionizing adjuvant development: harnessing AI for next-generation cancer vaccines.

Wan-Ying Zhang, Xiao-Li Zheng, Paolo Saul Coghi, Jun-Hui Chen, Bing-Jun Dong, Xing-Xing Fan
Author Information
  1. Wan-Ying Zhang: Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macao, Macao SAR, China.
  2. Xiao-Li Zheng: Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macao, Macao SAR, China.
  3. Paolo Saul Coghi: Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macao, Macao SAR, China.
  4. Jun-Hui Chen: Intervention and Cell Therapy Center, Peking University Shenzhen Hospital, Shenzhen, China.
  5. Bing-Jun Dong: Gynecology Department, Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine, Zhuhai, China.
  6. Xing-Xing Fan: Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macao, Macao SAR, China.
PMID: 39206192 DOI: 10.3389/fimmu.2024.1438030

Abstract

With the COVID-19 pandemic, the importance of vaccines has been widely recognized and has led to increased research and development efforts. Vaccines also play a crucial role in cancer treatment by activating the immune system to target and destroy cancer cells. However, enhancing the efficacy of cancer vaccines remains a challenge. Adjuvants, which enhance the immune response to antigens and improve vaccine effectiveness, have faced limitations in recent years, resulting in few novel adjuvants being identified. The advancement of artificial intelligence (AI) technology in drug development has provided a foundation for adjuvant screening and application, leading to a diversification of adjuvants. This article reviews the significant role of tumor vaccines in basic research and clinical treatment and explores the use of AI technology to screen novel adjuvants from databases. The findings of this review offer valuable insights for the development of new adjuvants for next-generation vaccines.

Keywords

AI drug discovery cancer immune agonist small molecular vaccine adjuvant

References

  1. Expert Rev Mol Diagn. 2009 May;9(4):325-41 [PMID: 19435455]
  2. Nucleic Acids Res. 2016 Jan 4;44(D1):D1202-13 [PMID: 26400175]
  3. Front Immunol. 2024 Feb 23;15:1348305 [PMID: 38464539]
  4. Vaccine. 2021 Aug 23;39(36):5162-5172 [PMID: 34362601]
  5. Sci Transl Med. 2015 Apr 15;7(283):283ra52 [PMID: 25877890]
  6. NPJ Vaccines. 2021 Jan 21;6(1):13 [PMID: 33479242]
  7. J Biomol Screen. 1999;4(2):67-73 [PMID: 10838414]
  8. Trends Pharmacol Sci. 2019 Aug;40(8):592-604 [PMID: 31320117]
  9. Biomaterials. 2018 May;164:38-53 [PMID: 29482062]
  10. Clin Cancer Res. 2016 Feb 1;22(3):680-90 [PMID: 26832745]
  11. Drug Des Discov. 2000;17(1):4-12 [PMID: 10928446]
  12. Eur Cytokine Netw. 2000 Sep;11(3):362-71 [PMID: 11022119]
  13. Clin Cancer Res. 2022 Feb 15;28(4):677-688 [PMID: 34716197]
  14. Artif Intell Rev. 2022;55(3):1947-1999 [PMID: 34393317]
  15. Clin Microbiol Infect. 2022 Sep;28(9):1263-1271 [PMID: 35436611]
  16. Chem Res Toxicol. 2019 Apr 15;32(4):536-547 [PMID: 30907586]
  17. Nat Mach Intell. 2021 Jan;3(1):68-75 [PMID: 35603127]
  18. Trends Immunol. 2020 Jun;41(6):493-511 [PMID: 32381382]
  19. Nat Rev Drug Discov. 2021 Jun;20(6):454-475 [PMID: 33824489]
  20. Nucleic Acids Res. 2002 Jan 1;30(1):47-9 [PMID: 11752250]
  21. Molecules. 2015 Jul 22;20(7):13384-421 [PMID: 26205061]
  22. Lancet. 2011 Jan 1;377(9759):31-41 [PMID: 21144578]
  23. Vaccine. 2010 Apr 19;28(18):3080-5 [PMID: 20197136]
  24. J Chem Inf Model. 2020 Dec 28;60(12):6065-6073 [PMID: 33118813]
  25. Front Bioeng Biotechnol. 2022 Jul 22;10:941077 [PMID: 35935487]
  26. Expert Rev Vaccines. 2011 Apr;10(4):401-3 [PMID: 21506635]
  27. Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:573-589 [PMID: 31518513]
  28. Bioinformatics. 2004 Nov 22;20(17):3206-13 [PMID: 15231534]
  29. Cell Res. 2020 Nov;30(11):966-979 [PMID: 32839553]
  30. Eur J Med Chem. 2022 Jan 15;228:114022 [PMID: 34871843]
  31. Nucleic Acids Res. 2021 Jan 8;49(D1):D498-D508 [PMID: 33211880]
  32. Future Med Chem. 2018 Nov;10(22):2641-2658 [PMID: 30499744]
  33. Cell. 2020 Oct 15;183(2):347-362.e24 [PMID: 33064988]
  34. Cancer Res. 2010 Apr 1;70(7):2595-603 [PMID: 20233880]
  35. J Mol Graph Model. 2010 Sep;29(2):157-70 [PMID: 20579912]
  36. Front Robot AI. 2019 Nov 05;6:108 [PMID: 33501123]
  37. Nat Rev Drug Discov. 2019 Jun;18(6):463-477 [PMID: 30976107]
  38. Viruses. 2023 Jun 26;15(7): [PMID: 37515128]
  39. J Comput Aided Mol Des. 2013 Mar;27(3):221-34 [PMID: 23579614]
  40. Urol Oncol. 2021 Feb;39(2):121-129 [PMID: 33262028]
  41. Expert Rev Vaccines. 2013 Jul;12(7):809-19 [PMID: 23885825]
  42. Gates Open Res. 2018 Jul 10;2:31 [PMID: 30234197]
  43. Mol Inform. 2022 Jan;41(1):e2000181 [PMID: 33274845]
  44. J Med Chem. 2022 Aug 11;65(15):10691-10706 [PMID: 35917397]
  45. Annu Rev Immunol. 2002;20:709-60 [PMID: 11861616]
  46. Biomaterials. 2018 May;163:67-75 [PMID: 29454236]
  47. J Med Chem. 2002 Jun 6;45(12):2615-23 [PMID: 12036371]
  48. Science. 2017 Jul 7;357(6346):22-27 [PMID: 28684483]
  49. Nucleic Acids Res. 2010 Jan;38(Database issue):D480-7 [PMID: 19948758]
  50. Acc Chem Res. 2022 Sep 20;55(18):2660-2671 [PMID: 36048514]
  51. Vaccines (Basel). 2021 Aug 17;9(8): [PMID: 34452042]
  52. Structure. 2017 Aug 1;25(8):1163-1174 [PMID: 28768162]
  53. J Immunother Cancer. 2021 Aug;9(8): [PMID: 34413169]
  54. J Immunother Cancer. 2021 May;9(5): [PMID: 34035112]
  55. Biochem Pharmacol. 2020 Aug;178:114042 [PMID: 32445869]
  56. Biomedicines. 2022 Apr 17;10(4): [PMID: 35453671]
  57. J Health Econ. 2016 May;47:20-33 [PMID: 26928437]
  58. Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669 [PMID: 33629336]
  59. J Clin Oncol. 1988 Dec;6(12):1811-4 [PMID: 3199166]
  60. Immunotherapy. 2018 Feb;10(2):149-160 [PMID: 29260623]
  61. Nature. 2018 Dec;564(7736):439-443 [PMID: 30405246]
  62. J Infect Dis. 2021 Sep 30;224(12 Suppl 2):S343-S351 [PMID: 34590138]
  63. Nat Med. 2023 Mar;29(3):748-752 [PMID: 36720271]
  64. J Exp Med. 2018 May 7;215(5):1287-1299 [PMID: 29622565]
  65. Pharmaceutics. 2021 Dec 28;14(1): [PMID: 35056969]
  66. Sci Eng Ethics. 2016 Apr;22(2):549-65 [PMID: 26026966]
  67. J Chem Inf Model. 2018 Feb 26;58(2):207-211 [PMID: 29320180]
  68. J Immunol. 2007 Feb 15;178(4):2171-81 [PMID: 17277122]
  69. Clin Cancer Res. 2015 Feb 15;21(4):712-20 [PMID: 25524312]
  70. Vaccine. 2008 Aug 26;26(36):4676-85 [PMID: 18640167]
  71. Front Med (Lausanne). 2023 Nov 10;10:1322157 [PMID: 38020110]
  72. Brief Bioinform. 2021 Jul 20;22(4): [PMID: 33140820]
  73. EMBO J. 1992 Nov;11(11):3887-95 [PMID: 1396582]
  74. Cancer J. 2010 Jul-Aug;16(4):382-91 [PMID: 20693851]
  75. Sci Data. 2022 Jun 2;9(1):263 [PMID: 35654801]
  76. Life Sci Alliance. 2018 Nov 28;1(6):e201800098 [PMID: 30515477]
  77. Nanomedicine. 2018 Feb;14(2):237-246 [PMID: 29127039]
  78. J Inflamm (Lond). 2017 Jun 7;14:11 [PMID: 28596706]
  79. Molecules. 2020 Jun 17;25(12): [PMID: 32560527]
  80. Acta Crystallogr B. 2002 Jun;58(Pt 3 Pt 1):380-8 [PMID: 12037359]
  81. Lancet Neurol. 2022 Sep;21(9):830-842 [PMID: 35963264]
  82. Nucleic Acids Res. 2013 Jan;41(Database issue):D456-63 [PMID: 23180789]
  83. Trends Pharmacol Sci. 2019 Aug;40(8):577-591 [PMID: 31326235]
  84. Nat Biotechnol. 2015 Nov;33(11):1201-10 [PMID: 26501954]
  85. Commun Biol. 2021 Jun 8;4(1):699 [PMID: 34103659]
  86. SN Comput Sci. 2021;2(4):296 [PMID: 34056624]
  87. Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11301-6 [PMID: 9736731]
  88. Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W783-6 [PMID: 15980585]
  89. Nanomedicine. 2014 Apr;10(3):503-14 [PMID: 24103304]
  90. Methods Mol Biol. 2022;2410:131-146 [PMID: 34914045]
  91. Nat Rev Drug Discov. 2019 Jan;18(1):41-58 [PMID: 30310233]
  92. Sci Rep. 2013;3:1445 [PMID: 23486013]
  93. Clin Ther. 2019 Aug;41(8):1414-1426 [PMID: 31248680]
  94. Mol Cell. 2019 Nov 7;76(3):359-370 [PMID: 31668929]
  95. Oncotarget. 2018 Jan 10;9(11):10110-10117 [PMID: 29515795]
  96. Nucleic Acids Res. 2022 Jan 7;50(D1):D1398-D1407 [PMID: 34718717]
  97. J Cheminform. 2022 Oct 14;14(1):69 [PMID: 36242073]
  98. Immunity. 2016 Nov 15;45(5):963-973 [PMID: 27851925]
  99. Pharmaceuticals (Basel). 2022 May 23;15(5): [PMID: 35631472]
  100. N Engl J Med. 1999 Nov 18;341(21):1606-9 [PMID: 10564693]
  101. Hum Vaccin Immunother. 2014;10(11):3139-45 [PMID: 25483653]
  102. Comb Chem High Throughput Screen. 2011 Dec;14(10):840-60 [PMID: 21843146]
  103. J Chem Inf Model. 2020 Nov 23;60(11):5375-5381 [PMID: 32794768]
  104. J Immunol Res. 2020 Nov 17;2020:5825401 [PMID: 33282961]
  105. Vaccine. 2005 Apr 15;23(21):2740-50 [PMID: 15780721]
  106. Vaccines (Basel). 2023 Mar 17;11(3): [PMID: 36992279]
  107. Front Immunol. 2019 Aug 27;10:2022 [PMID: 31507611]
  108. Front Pharmacol. 2022 Aug 09;13:956501 [PMID: 36016573]
  109. Sci Transl Med. 2011 Apr 27;3(80):80ps16 [PMID: 21525397]
  110. Immune Netw. 2022 Feb 14;22(1):e4 [PMID: 35291652]
  111. J Enzyme Inhib Med Chem. 2022 Dec;37(1):226-235 [PMID: 34894949]
  112. ACS Nano. 2015 May 26;9(5):4925-38 [PMID: 25898266]
  113. Oncotarget. 2016 May 24;7(21):30323-35 [PMID: 27083005]
  114. Birth Defects Res. 2018 Jun 1;110(10):840-850 [PMID: 29436169]
  115. Drug Discov Today Technol. 2013 Dec;10(4):e501-8 [PMID: 24451641]
  116. Int Immunol. 2016 Jul;28(7):329-38 [PMID: 27006304]
  117. Nat Mater. 2018 Feb;17(2):187-194 [PMID: 29300052]
  118. Mol Inform. 2023 Nov;42(11):e202300128 [PMID: 37679293]
  119. Nat Rev Immunol. 2016 Oct;16(10):626-38 [PMID: 27546235]
  120. Acta Crystallogr B Struct Sci Cryst Eng Mater. 2016 Apr;72(Pt 2):171-9 [PMID: 27048719]
  121. Front Immunol. 2022 Sep 05;13:944872 [PMID: 36131910]
  122. J Chem Inf Model. 2017 Aug 28;57(8):1757-1772 [PMID: 28696688]
  123. Integr Med Res. 2020 Sep;9(3):100434 [PMID: 32632356]
  124. Proc R Soc Lond B Biol Sci. 1989 Mar 22;236(1283):125-40 [PMID: 2565577]
  125. Proc R Soc Lond B Biol Sci. 1989 Mar 22;236(1283):141-62 [PMID: 2565578]
  126. Nucleic Acids Res. 2019 Jan 8;47(D1):D930-D940 [PMID: 30398643]
  127. Front Immunol. 2022 Mar 03;13:812774 [PMID: 35309296]
  128. Sci Adv. 2018 Jul 25;4(7):eaap7885 [PMID: 30050984]
  129. Molecules. 2020 Oct 20;25(20): [PMID: 33092204]
  130. Nucleic Acids Res. 2016 Jan 4;44(D1):D1045-53 [PMID: 26481362]
  131. Immunity. 2014 Nov 20;41(5):830-42 [PMID: 25517615]
  132. Nat Rev Drug Discov. 2018 Feb;17(2):97-113 [PMID: 29242609]
  133. Nat Biotechnol. 2014 Jan;32(1):40-51 [PMID: 24406927]
  134. IEEE Trans Pattern Anal Mach Intell. 2022 Dec;44(12):8861-8873 [PMID: 34652996]
  135. Biomark Res. 2022 Dec 7;10(1):89 [PMID: 36476317]
  136. Vaccine. 2021 Sep 24;39(40):5940-5953 [PMID: 34420786]
  137. J Immunol. 2000 Aug 1;165(3):1228-35 [PMID: 10903720]
  138. Front Immunol. 2022 Nov 03;13:1005937 [PMID: 36405719]
  139. Biomacromolecules. 2019 Feb 11;20(2):854-870 [PMID: 30608149]
  140. Curr Opin Chem Biol. 2022 Oct;70:102172 [PMID: 35785601]
  141. Drug Discov Today. 2012 Feb;17(3-4):104-9 [PMID: 22001144]
  142. Pharmaceutics. 2020 Mar 15;12(3): [PMID: 32183437]
  143. Science. 2019 Jan 11;363(6423): [PMID: 30498165]
  144. Cancer Immunol Immunother. 2014 Jul;63(7):721-35 [PMID: 24711084]
  145. Cell Mol Immunol. 2012 Nov;9(6):434-8 [PMID: 23085951]
  146. Nature. 2024 May;629(8013):937-944 [PMID: 38720067]
  147. Med Res Rev. 2008 May;28(3):413-44 [PMID: 17694549]
  148. Adv Drug Deliv Rev. 2020;154-155:102-122 [PMID: 32650041]
  149. Science. 2013 Feb 15;339(6121):786-91 [PMID: 23258413]
  150. Curr Opin Pharmacol. 2018 Aug;41:34-41 [PMID: 29677646]
  151. BMC Pharmacol Toxicol. 2019 Jan 08;20(1):2 [PMID: 30621790]
  152. Nat Biotechnol. 2017 Jul 12;35(7):604-605 [PMID: 28700560]
  153. Eur J Immunol. 1998 Jun;28(6):2045-54 [PMID: 9645386]
  154. Mar Drugs. 2021 Dec 25;20(1): [PMID: 35049884]
  155. ChemMedChem. 2022 Jul 5;17(13):e202200002 [PMID: 35413149]
  156. Mini Rev Med Chem. 2014 Jan;14(1):35-55 [PMID: 24195665]
  157. Vaccine. 2021 Sep 24;39(40):5866-5875 [PMID: 34456075]
  158. Acta Pharm Sin B. 2022 Dec;12(12):4287-4308 [PMID: 36562003]
  159. Front Immunol. 2018 Aug 22;9:1914 [PMID: 30186285]
  160. Biomedicines. 2022 Dec 27;11(1): [PMID: 36672572]
  161. J Mater Chem B. 2021 May 12;9(18):3892-3899 [PMID: 33928989]
  162. Methods Mol Biol. 2019;1939:119-138 [PMID: 30848459]
  163. J Immunol. 1991 Sep 15;147(6):1759-64 [PMID: 1890302]
  164. J Mater Chem B. 2016 Sep 7;4(33):5496-5509 [PMID: 30774955]
  165. Small. 2022 Apr;18(14):e2107461 [PMID: 35152555]
  166. J Cheminform. 2020 Nov 17;12(1):70 [PMID: 33292482]
  167. Nat Commun. 2021 Nov 4;12(1):6370 [PMID: 34737262]
  168. J Mol Model. 2022 Mar 24;28(4):100 [PMID: 35325303]
  169. Cell Mol Life Sci. 2022 Oct 12;79(11):547 [PMID: 36224474]
  170. Cancers (Basel). 2022 Dec 11;14(24): [PMID: 36551577]
  171. Pathogens. 2021 Apr 21;10(5): [PMID: 33919442]
  172. Nat Commun. 2023 Mar 22;14(1):1573 [PMID: 36949064]
  173. Methods Mol Biol. 2017;1647:255-266 [PMID: 28809009]
  174. Lancet Infect Dis. 2021 Jul;21(7):950-961 [PMID: 33705727]
  175. Expert Opin Drug Discov. 2015 Dec;10(12):1283-300 [PMID: 26358617]
  176. Front Immunol. 2024 Feb 15;15:1287824 [PMID: 38433837]
  177. Methods Mol Biol. 2017;1494:15-27 [PMID: 27718183]
  178. Vaccine. 2022 May 20;40(23):3182-3192 [PMID: 35465982]
  179. N Engl J Med. 2010 Jul 29;363(5):411-22 [PMID: 20818862]
  180. Int J Mol Sci. 2022 Dec 15;23(24): [PMID: 36555602]
  181. Front Immunol. 2022 Dec 15;13:1059173 [PMID: 36591275]
  182. Cancer Immunol Immunother. 2009 Apr;58(4):517-30 [PMID: 18719913]
  183. Front Immunol. 2020 Nov 11;11:580974 [PMID: 33262759]
  184. Blood. 2004 Mar 15;103(6):2162-9 [PMID: 14630815]
  185. Drug Discov Today. 2009 Feb;14(3-4):147-54 [PMID: 19135549]
  186. Discov Oncol. 2021 Aug 18;12(1):27 [PMID: 35201440]
  187. J Comput Biol. 2019 Feb;26(2):152-171 [PMID: 30495984]
  188. J Chem Phys. 2020 Jul 28;153(4):044123 [PMID: 32752663]
  189. Nature. 2008 Oct 2;455(7213):674-8 [PMID: 18724357]
  190. Int J Mol Sci. 2022 Nov 27;23(23): [PMID: 36499173]
  191. Curr Top Med Chem. 2016;16(19):2088-106 [PMID: 26881716]
  192. ACS Cent Sci. 2018 Feb 28;4(2):268-276 [PMID: 29532027]
  193. ACS Cent Sci. 2018 Nov 28;4(11):1520-1530 [PMID: 30555904]
  194. Annu Rev Immunol. 2015;33:257-90 [PMID: 25581309]
  195. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082 [PMID: 29126136]
  196. Pharmaceuticals (Basel). 2022 Jun 17;15(6): [PMID: 35745675]
  197. Cancer J. 2010 Jul-Aug;16(4):354-9 [PMID: 20693847]
  198. Eur J Immunol. 2021 Jul;51(7):1686-1697 [PMID: 33860535]
  199. Future Microbiol. 2022 Feb;17:185-197 [PMID: 34856810]
  200. Curr Mol Med. 2002 Sep;2(6):545-56 [PMID: 12243247]
  201. Curr Pharm Des. 2016;22(5):572-81 [PMID: 26601966]
  202. Biostatistics. 2019 Apr 1;20(2):273-286 [PMID: 29394327]
  203. J Comput Aided Mol Des. 2021 May;35(5):679-694 [PMID: 33905074]
  204. Artif Intell Rev. 2023;56(7):5975-6037 [PMID: 36415536]
  205. Front Immunol. 2014 Sep 12;5:434 [PMID: 25309535]
  206. Nature. 1995 Apr 6;374(6522):546-9 [PMID: 7700380]
  207. Nat Rev Urol. 2018 Oct;15(10):615-625 [PMID: 29991725]
  208. Proc R Soc Lond B Biol Sci. 1989 Mar 22;236(1283):101-13 [PMID: 2565575]
  209. Nat Biotechnol. 2019 Sep;37(9):1038-1040 [PMID: 31477924]
  210. Future Med Chem. 2022 Feb;14(4):207-219 [PMID: 34809496]
  211. Target Oncol. 2021 Mar;16(2):121-152 [PMID: 33512679]
  212. NPJ Vaccines. 2023 Mar 15;8(1):39 [PMID: 36922512]

MeSH Term

Humans
Cancer Vaccines
Artificial Intelligence
Adjuvants, Immunologic
Neoplasms
COVID-19
SARS-CoV-2
Animals
Vaccine Development
Drug Development

Chemicals

Cancer Vaccines
Adjuvants, Immunologic
Journal Article Review
Article has an altmetric score of 2

Word Cloud

Created with Highcharts 10.0.0vaccinescanceradjuvantsAIdevelopmentimmuneadjuvantresearchroletreatmentvaccinenoveltechnologydrugnext-generationCOVID-19pandemicimportancewidelyrecognizedledincreasedeffortsVaccinesalsoplaycrucialactivatingsystemtargetdestroycellsHoweverenhancingefficacyremainschallengeAdjuvantsenhanceresponseantigensimproveeffectivenessfacedlimitationsrecentyearsresultingidentifiedadvancementartificialintelligenceprovidedfoundationscreeningapplicationleadingdiversificationarticlereviewssignificanttumorbasicclinicalexploresusescreendatabasesfindingsreviewoffervaluableinsightsnewRevolutionizingdevelopment:harnessingdiscoveryagonistsmallmolecular

Similar Articles

Cited By